- Barrons.com•4 days ago
The three companies below look likely to reward patient investors - and impatient ones, according to a recent report by Morgan Stanley. Long-term, these companies have favorable exposure to rising wealth in China. In a 118-page report released this week, analysts, strategists and economists at Morgan Stanley argue that China will avoid a feared financial shock and instead gradually shift to higher-value economic activity and enjoy continued growth, reaching high-income status by 2027.
- Reuters•2 years ago
China will allow online sales of prescription drugs as early as this month, a policy that will open up an over 1 trillion yuan market to online pharmacy operators like Alibaba Group Holding Ltd and Wal-Mart ...
- Bloomberg•2 years ago
Sinopharm Group Co. (1099) said it is raising about HK$5.55 billion ($716 million) from a share sale to help expand its drug distribution network. The stock fell. The Chinese drug distributor is selling ...
1099.HK : Summary for SINOPHARM - Yahoo Finance
HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
|Day's Range||35.85 - 36.80|
|52 Week Range||27.70 - 42.50|
|PE Ratio (TTM)||22.54|
|Dividend & Yield||0.06 (1.37%)|
|1y Target Est||N/A|